Skip to main content
Fig. 3 | BMC Gastroenterology

Fig. 3

From: Comparative efficacy and safety of subcutaneous infliximab and vedolizumab in patients with Crohn’s disease and ulcerative colitis included in randomised controlled trials

Fig. 3

Comparison of IFX SC1 versus VDZ for key efficacy outcomes in patients with ulcerative colitis. 1Results from the induction period were analysed for patients included in the IFX SC group who had received IFX IV induction therapy. 2Evaluated based on partial Mayo score. 3Data for VDZ are based on data from a single arm of the VARSITY trial. 4Evaluated based on total Mayo score. Error bars show 95% CIs. CI: Confidence interval; IFX: Infliximab; IV: Intravenous; LOE: Lack of efficacy; SC: Subcutaneous; VDZ: Vedolizumab

Back to article page

BMC Gastroenterology

ISSN: 1471-230X

Contact us